Trial reportClinical ophthalmology (Auckland, N.Z.)2025
A Prospective Single-Center Clinical Trial Comparing Short-Term Outcomes of a Novel Non-Cavitating Handheld Lensectomy Device versus Phacoemulsification.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the short-term outcomes of a non-cavitating lensectomy device (MICOR) to phacoemulsification. Patients and Methods: This was a two-arm prospective open-label clinical trial. Patients with visually significant cataracts at a single academic center between March and December 2023 were consecutively enrolled to undergo cataract surgery using either MICOR or phacoemulsification for nuclear fragmentation and lens removal. Adverse events (AE), lensectomy time, fluid use, and ultrasound energy use were assessed intraoperatively. Visual acuity, refraction, and AE were assessed on postoperative day one. Results: A total of 34 eyes of 23 patients were included in the MICOR arm and 50 eyes of 32 patients in the phacoemulsification arm. No difference (p = 0.727) in logMAR best corrected distance visual acuity was observed postoperatively between MICOR (0.14 ± 0.25) and phacoemulsification (0.16 ± 0.33), nor was any difference observed in AE rates [3% versus 8%, respectively (p = 0.644)]. Lens removal time was faster with MICOR [209 vs 255 s (p = 0.003)], including for grade 2 cataracts [203 vs 237 s (p = 0.008)]. Irrigation volume was less for MICOR [33 vs 62 mL (p < 0.001)], including for grade 2 [34 vs 60 mL (p < 0.001)] and 3 cataracts [36 vs 60 mL (p = 0.004)]. Mean cumulative dissipated energy for phacoemulsification was 8.7. Conclusion: Compared to phacoemulsification, MICOR has similar visual outcomes and adverse event rates while requiring less time, irrigation fluid, and ultrasound energy, suggesting MICOR is a viable alternative to phacoemulsification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.